drugset / Trial / NCT02968433

The Stanford Parkinson's Disease Plasma Study

NCT02968433 ↗

Phase 1 Completed 16 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate that young plasma infusions can be performed safely in patients with Parkinson's Disease (PD). Secondary outcomes will include behavioral and laboratory data that will support the next study that will inquire whether young plasma infusions improve or slow the progression of cognitive, mood and/or motor impairment and rate markers of the disease.

Timeline

Start
2016-11
Primary completion
2019-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject young plasma Unknown 1 unknown Intravenous

Indications